CytomX Therapeutics Inc [CTMX] stock is trading at $0.93, down -14.83%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CTMX shares have gain 15.76% over the last week, with a monthly amount glided 85.57%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Piper Sandler upgraded its rating to Overweight on May 28, 2024, and elevated its price target to $3.50. On May 09, 2024, upgrade upgraded it’s rating to Outperform but maintained its price target of $8 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $8 on May 06, 2024. JP Morgan upgraded its rating to a Neutral. BMO Capital Markets downgraded its rating to Market Perform for this stock on November 14, 2022, and downed its price target to $2.60. In a note dated July 07, 2022, Wedbush downgraded an Neutral rating on this stock and revised its target price from $6 to $2.
CytomX Therapeutics Inc [CTMX] stock has fluctuated between $0.40 and $2.81 over the past year. Currently, Wall Street analysts expect the stock to reach $5.73 within the next 12 months. CytomX Therapeutics Inc [NASDAQ: CTMX] shares were valued at $0.93 at the most recent close of the market. An investor can expect a potential return of 516.13% based on the average CTMX price forecast.
Analyzing the CTMX fundamentals
CytomX Therapeutics Inc [NASDAQ:CTMX] reported sales of 138.10M for the trailing twelve months, which represents a growth of 43.17%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.23%, and Net Profit Margin reading is 0.23%. To continue investigating profitability, this company’s Return on Assets is posted at 0.26, Equity is -1.47 and Total Capital is 0.72. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -20.58.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7911 points at the first support level, and at 0.6537 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1829, and for the 2nd resistance point, it is at 1.4373.
Ratios To Look Out For
For context, CytomX Therapeutics Inc’s Current Ratio is 1.25. In addition, the Quick Ratio stands at 1.25 and the Cash Ratio stands at 0.44. Considering the valuation of this stock, the price to sales ratio is 0.54 and price to earnings (TTM) ratio is 2.36.
Transactions by insiders
Recent insider trading involved McCarthy Sean A., CEO, that happened on Mar 18 ’25 when 37656.0 shares were sold. Chief Financial Officer, Ogden Christopher completed a deal on Mar 18 ’25 to sell 8551.0 shares. Meanwhile, Chief Medical Officer Chu Yu-Waye sold 4025.0 shares on Mar 18 ’25.
